Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Research In Brief

This article was originally published in The Gray Sheet

Executive Summary

Ortho fee journal disclosures subpar: Less than half of inspected journal articles with authors who received $1 million or more in consulting fees from one of five orthopedic device firms in 2007 disclosed the financial relationship, researchers reported in an Archives of Internal Medicine study posted online Sept. 13. The team from the nonprofit Institute on Medicine as a Profession looked at online disclosures from Biomet, Johnson & Johnson/DePuy, Smith & Nephew, Stryker and Zimmer, which each started posting consultant payment data following a 2007 settlement with the U.S. Department of Justice on kickback allegations. They identified the 41 recipients of at least $1 million in 2007 and sampled each individual's most recent articles over the period of Jan. 1, 2008, through Jan. 15, 2009. Forty-six percent of the 95 sampled articles included a disclosure of the relationship, while only about 7% provided any information on the payment amounts. The disclosure rate was 54% for authors who were either listed first, last (senior position) or were sole authors compared to 32% for middle authors. No correlation was identified between disclosures and the stringency of a journal's disclosure policies. The researchers from IMAP, a group focused on researching and advocating for professionalism in medicine, recommended that journals collect more comprehensive information on commercial relationships from physicians and, in particular, make good use of the centralized disclosures on a government database that will go live on 2013 as a requirement of the sunshine provisions in the Affordable Care Act (1"The Gray Sheet" April 12, 2010)

You may also be interested in...



Panel Narrowly Recommends Medtronic Spine Treatment After Tough Scrutiny

An FDA advisory panel cast a mixed vote on July 27 in support of Medtronic's Amplify rhBMP-2 Matrix spinal treatment, reflecting disagreement about safety and the reliability of some clinical data

Sunshine Nationwide: Fed Disclosure Law Meets Some, Not All, Industry Goals

Device industry representatives say they are happy that the new federal mandate for publicly disclosing payments to physicians includes some pre-emptive authority over states, but they hope to convince lawmakers to strengthen that authority before the new rules take effect

Cosmetic And Personal Care Trademark Review: 16 April

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT029410

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel